Actively Recruiting
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients
Led by Pierian Biosciences · Updated on 2025-02-28
100
Participants Needed
1
Research Sites
192 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, non-randomized, observational, clinical development study. Pierian Biosciences is utilizing ChemoINTEL and ImmunoINTEL assay measurements in human tumour cells from patients with advanced stage epithelial ovarian cancer (EOC) to develop a mathematical algorithm which will be able to predict a patient's tumour's sensitivity to specific chemotherapy drugs. The study involves using a sample of tumour biopsy taken during standard of care surgery, with a matched blood sample if possible. Medical history, pathology information and information on chemotherapy for up to 6 cycles will be requested. The information will then be used to developed an algorithm to predict tumour sensitivity to treatment.
CONDITIONS
Official Title
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patient Clinical Response to Administered Chemotherapy in Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female aged 18 years or older
- Diagnosis by pathology of advanced stage epithelial ovarian cancer, primary peritoneal carcinomatosis, or fallopian tube carcinoma (newly diagnosed or recurrent)
- Provided an evaluable tumor or peritoneal fluid specimen before starting chemotherapy for ChemoINTEL assay
- Received at least 3 cycles of standard chemotherapy including agents such as carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, fluorouracil, gemcitabine, ifosfamide, irinotecan, oxaliplatin, paclitaxel, pemetrexed, topotecan, vinorelbine, or bevacizumab
- Underwent evaluation after the 3rd and 6th chemotherapy cycles to document response by RECIST 2009 v1.1, CA-125 KELIM Scoring, or circulating tumor DNA monitoring
- Signed an informed consent form
You will not qualify if you...
- Has not signed an informed consent form
- Has a cancer diagnosis other than advanced stage epithelial ovarian cancer
- Did not receive standard chemotherapy agents listed in the study
- Did not have sufficient viable cells from tumor or peritoneal fluid samples collected before chemotherapy for assay analysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Liverpool Women's NHS Foundation Trust
Liverpool, Merseyside, United Kingdom, L8 7SS
Actively Recruiting
Research Team
N
Norman Purvis, PhD
CONTACT
M
Maria Maguire, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here